Buffer-Free Rotavirus Vaccine Formulation for Acid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rotavirus vaccines require buffers or antacids to neutralize stomach acidity, increasing dosage volume and complexity, and are not stable enough for long-term storage and transportation, particularly in developing countries.
Innovation Solution
Development of a buffer-free, low-dose volume rotavirus vaccine formulation using the 116E strain, stable at acidic pH and capable of maintaining vaccine titer for extended periods without reconstitution, suitable for storage at -20°C for 5 years and administration without additional buffers or antacids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If buffers or antacids are added to rotavirus vaccine formulations to neutralize stomach acidity, then the vaccine stability and immune response are improved, but the dosage volume and formulation complexity increase
Solution Approach 1:
The patent removes buffers and antacids from the vaccine formulation entirely, extracting the problematic components that caused complexity while maintaining vaccine stability through alternative means (optimized pH range of 6.0-7.5 and cold chain storage)
Solution Approach 2:
The patent changes the pH parameter of the formulation to a neutral range (6.0-7.5) that does not require acid neutralization, fundamentally altering the chemical environment to eliminate the need for buffering agents
2Reliability
If buffers are included in rotavirus vaccine formulations to protect against stomach acid, then the vaccine efficacy is improved, but the dosage volume increases
Solution Approach 1:
The patent extracts buffers from the formulation, reducing the total volume of substances administered while maintaining efficacy through the neutral pH formulation approach
3Reliability
If rotavirus vaccines are formulated with buffers for acid neutralization, then the immune response is enhanced, but the storage and transportation stability is reduced
Solution Approach 1:
The patent removes buffers that compromised storage stability, achieving both improved stability and maintained immune response through the buffer-free neutral pH formulation
Solution Approach 2:
The patent changes the pH parameter to a neutral range (6.0-7.5) that provides both storage stability and immune efficacy without requiring acid-neutralizing buffers
4Reliability
If additional buffers or antacids are administered with the vaccine, then the vaccine protection is improved, but the ease of operation is reduced
Solution Approach 1:
The patent extracts the need for separate buffer administration, making the vaccine a single-component product that requires only refrigeration and oral administration without additional steps
Solution Approach 2:
The neutral pH formulation serves multiple functions simultaneously: it is stable during storage, requires no additional buffers for administration, and provides adequate protection against stomach acid, eliminating the need for separate buffer doses
Data Source
AI summary
A buffer free, acid stable, low dose volume rotavirus vaccine is disclosed. The vaccine is available in dose volume of less than 1 ml per dose for oral administration and it is without any buffer. The vaccine also does not require pre or post administration of any antacid at the time of oral administration of the vaccine to the subject to neutralize the stomach acid. The vaccine exemplifies nominal drop in vaccine titer at pH 2-4 for a time span of 30 minutes. The vaccine is stable at −20° C. for at least 60 months.